Browse

Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
Cho, Byoung Chul; Kim, Dong-Wan; Park, Keunchil; Lee, Jong Seok; Yoo, Seung Soo; Kang, Jin Hyoung; Lee, Sung Yong; Kim, Cheol Hyeon; Jang, Seung Hun; Kim, Young-Chul; Yoon, Hyoung-Kyu; Han, Ji-Youn; Kim, Sang-We
Issue Date
2020-03
Citation
Current Medical Research and Opinion, Vol.36 No.3, pp.477-482
Keywords
Osimertinibnon-small cell lung cancerNSCLCEGFR T790M mutationEGFR-TKI therapy
Abstract
Objective: ASTRIS is a large real-world, open-label, multinational clinical study of osimertinib in patients with epidermal growth factor receptor (EGFR) T790M mutation-positive advanced non-small cell lung cancer (NSCLC) who have previously received a tyrosine kinase inhibitor (TKI). We report data from the Korean ASTRIS subgroup. Methods: Adult patients with locally advanced or metastatic NSCLC with a confirmed T790M mutation, WHO performance status of 0-2 and prior EGFR-TKI therapy, received osimertinib 80 mg once daily. Efficacy outcomes were overall survival (OS), investigator-assessed response rate (RR) and progression-free survival (PFS), and time to treatment discontinuation (TTD). Results: At data cut-off (20 October 2017), 466 Korean patients were enrolled. Baseline EGFR molecular testing was mainly performed on biopsied tissue (75.1%). Baseline mutations co-occurring with T790M included exon 19 deletions (60.7%) and L858R (32.8%). 1-year OS was 82.7% (OS data not matured at data cut-off). Overall, RR was 71.0%, median PFS was 12.4 months and median TTD was 15.0 months. In patients with/without CNS metastases, RR was 68.0% and 79.6%, respectively; median PFS, 10.8 and 11.0 months, respectively; and median TTD, 11.2 and 14.7 months, respectively. Overall, 31.1% of patients experienced >= 1 adverse event (AE), leading to dose modification (12.0%), discontinuation (5.2%) or death (2.8%). Serious AEs (24.9%) included pulmonary embolism (1.7%), pleural effusion (1.7%), and pneumonia (1.5%). Conclusion: In this real-world subgroup analysis of Korean patients in the ASTRIS study, osimertinib demonstrated comparable clinical efficacy to that attained in the global ASTRIS study and other clinical trials, with no new safety concerns.
ISSN
0300-7995
URI
http://hdl.handle.net/10371/165198
DOI
https://doi.org/10.1080/03007995.2019.1676708
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse